公开(公告)号：US11267812B2

公开(公告)日：2022-03-08

申请号：US16099398

申请日：2017-05-17

Applicant: Mirati Therapeutics, Inc. ,  Array BioPharma Inc.

Inventor： John P. Fischer ,  Jay Bradford Fell ,  James F. Blake ,  Ronald Jay Hinklin ,  Macedonio J. Mejia ,  Erik James Hicken ,  Mark Joseph Chicarelli ,  John J. Gaudino ,  Guy P. A. Vigers ,  Laurence E. Burgess ,  Matthew Arnold Marx ,  James Gail Christensen ,  Matthew Randolph Lee ,  Pavel Savechenkov ,  Henry J. Zecca ,  Tony P. Tang

IPC: C07D471/04 ,  C07D519/00 ,  A61P35/00

Abstract: The present invention relates to compounds that inhibit KRas G12C. In particular, the present invention relates to compounds that irreversibly inhibit the activity of KRas G12C, pharmaceutical compositions comprising the compounds and methods of use therefor.

公开(公告)号：US11932633B2

公开(公告)日：2024-03-19

申请号：US17053273

申请日：2019-05-06

Applicant: Mirati Therapeutics, Inc. ,  Array BioPharma, Inc.

Inventor： Matthew Arnold Marx ,  Matthew Randolph Lee ,  James F. Blake ,  Mark Joseph Chicarelli ,  Jay Bradford Fell ,  John P. Fischer ,  Erik James Hicken ,  Pavel Savechenkov ,  Tony Tang ,  Guy P. A. Vigers ,  Henry J. Zecca

IPC: C07D413/06 ,  A61P35/00 ,  C07D413/04 ,  C07D413/14 ,  C07D417/14

CPC classification number: C07D413/14 ,  A61P35/00 ,  C07D413/06

Abstract: The present invention relates to compounds that inhibit KRas G12C. In particular, the present invention relates to compounds that irreversibly inhibit the activity of KRas G12C, pharmaceutical compositions comprising the compounds and methods of use therefor.

公开(公告)号：US20210380570A1

公开(公告)日：2021-12-09

申请号：US17053273

申请日：2019-05-06

Applicant: Mirati Therapeutics, Inc. ,  Array BioPharma, Inc.

Inventor： Matthew Arnold Marx ,  Matthew Randolph Lee ,  James F. Blake ,  Mark Joseph Chicarelli ,  Jay Bradford Fell ,  John P. Fischer ,  Erik James Hicken ,  Pavel Savechenkov ,  Tony Tang ,  Guy P.A. Vigers ,  Henry J. Zecca

IPC: C07D413/14 ,  C07D413/06 ,  A61P35/00

Abstract: The present invention relates to compounds that inhibit KRas G12C. In particular, the present invention relates to compounds that irreversibly inhibit the activity of KRas G12C, pharmaceutical compositions comprising the compounds and methods of use therefor.

公开(公告)号：US11220509B2

公开(公告)日：2022-01-11

申请号：US17219379

申请日：2021-03-31

Applicant: Mirati Therapeutics, Inc.

Inventor： Matthew Arnold Marx ,  Matthew Randolph Lee ,  Thomas P. Bobinski ,  Aaron Craig Burns ,  Nidhi Arora ,  James Gail Christensen ,  John Michael Ketcham

IPC: C07D487/04

Abstract: The present disclosure relates to compounds of Formula (I), or pharmaceutically, acceptable salts thereof, that inhibit Polycomb Repressive Complex 2 (PRC2) activity. In particular, the present disclosure relates to compounds, or pharmaceutically acceptable salts thereof pharmaceutical compositions and methods of use, such as methods of treating cancer using the compounds of Formula (I), or pharmaceutically acceptable salts thereof, and pharmaceutical compositions comprising compounds of Formula (I), or pharmaceutically acceptable salts thereof.

公开(公告)号：US20210032252A1

公开(公告)日：2021-02-04

申请号：US16966708

申请日：2019-01-29

Applicant: Mirati Therapeutics, Inc.

Inventor： Matthew Arnold Marx ,  Matthew Randolph Lee ,  Thomas P. Bobinski ,  Aaron Craig Burns ,  Nidhi Arora ,  James Gail Christensen ,  John Michael Ketcham

IPC: C07D487/04

Abstract: The present invention relates to compounds that inhibit Polycomb Repressive Complex 2 (PRC2) activity. In particular, the present invention relates to compounds, pharmaceutical compositions and methods of use, such as methods of treating cancer using the compounds and pharmaceutical compositions of the present invention.

公开(公告)号：US10266542B2

公开(公告)日：2019-04-23

申请号：US15921097

申请日：2018-03-14

Applicant: Mirati Therapeutics, Inc.

Inventor： Matthew Arnold Marx ,  Matthew Randolph Lee ,  Robert Anthony Galemmo ,  Thomas P. Bobinski

IPC: C07D491/048 ,  C07D519/00 ,  C07D471/04 ,  C07D495/04 ,  C07D498/04 ,  C07D513/04 ,  A61P35/00

Abstract: The present invention relates to compounds that inhibit EZH2 activity. In particular, the present invention relates to compounds, pharmaceutical compositions and methods of use, such as methods of treating cancer using the compounds and pharmaceutical compositions of the present invention.

公开(公告)号：US11485738B2

公开(公告)日：2022-11-01

申请号：US16966708

申请日：2019-01-29

Applicant: Mirati Therapeutics, Inc.

Inventor： Matthew Arnold Marx ,  Matthew Randolph Lee ,  Thomas P. Bobinski ,  Aaron Craig Burns ,  Nidhi Arora ,  James Gail Christensen ,  John Michael Ketcham

IPC: A61K31/519 ,  C07D487/04

Abstract: The present invention relates to compounds that inhibit Polycomb Repressive Complex 2 (PRC2) activity. In particular, the present invention relates to compounds, pharmaceutical compositions and methods of use, such as methods of treating cancer using the compounds and pharmaceutical compositions of the present invention.

公开(公告)号：US11091495B2

公开(公告)日：2021-08-17

申请号：US17116270

申请日：2020-12-09

Applicant: Mirati Therapeutics, Inc.

Inventor： Matthew Arnold Marx ,  Matthew Randolph Lee ,  Thomas P. Bobinski ,  Aaron Craig Burns ,  Nidhi Arora ,  James Gail Christensen ,  John Michael Ketcham

IPC: A61K31/519 ,  C07D487/04

Abstract: The present invention relates to compounds that inhibit Polycomb Repressive Complex 2 (PRC2) activity. In particular, the present invention relates to compounds, pharmaceutical compositions and methods of use, such as methods of treating cancer using the compounds of Formula (I) and pharmaceutical compositions of the present invention.

公开(公告)号：US20180265517A1

公开(公告)日：2018-09-20

申请号：US15921097

申请日：2018-03-14

Applicant: Mirati Therapeutics, Inc.

Inventor： Matthew Arnold Marx ,  Matthew Randolph Lee ,  Robert Anthony Galemmo ,  Thomas P. Bobinski

IPC: C07D491/048 ,  C07D519/00 ,  C07D471/04 ,  C07D495/04 ,  C07D498/04 ,  C07D513/04 ,  A61P35/00

CPC classification number: C07D491/048 ,  A61P35/00 ,  C07D471/04 ,  C07D495/04 ,  C07D498/04 ,  C07D513/04 ,  C07D519/00

Abstract: The present invention relates to compounds that inhibit EZH2 activity. In particular, the present invention relates to compounds, pharmaceutical compositions and methods of use, such as methods of treating cancer using the compounds and pharmaceutical compositions of the present invention.